Ubiquinone and nicotinamide treatment of patients with the 3243A→G mtDNA mutation
暂无分享,去创建一个
K. Majamaa | I. Hassinen | U. Tolonen | S. Winqvist | K. Reinikainen | A. Remes | E. Liimatta | J. Ranua
[1] K. Majamaa,et al. Hearing impairment in patients with 3243A→G mtDNA mutation: phenotype and rate of progression , 2001, Human Genetics.
[2] K. Abe,et al. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): Evaluation by noninvasive tissue oximetry , 1999, Journal of the Neurological Sciences.
[3] K. Majamaa,et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. , 1998, American journal of human genetics.
[4] N. Chu,et al. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. , 1997, European neurology.
[5] K. Majamaa,et al. Increase of blood NAD+ and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome. , 1996, Life sciences.
[6] P. Matthews,et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease , 1993, Neurology.
[7] P. Thuillier,et al. MELAS syndrome with mitochondrial tRNA Leu[UUR] mutation , 1992, Neurology.
[8] Y. Goto,et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS) , 1992, Neurology.
[9] N. Bresolin,et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial , 1990, Journal of the Neurological Sciences.
[10] K. Katayama,et al. Simultaneous determination of ubiquinone-10 and ubiquinol-10 in tissues and mitochondria by high performance liquid chromatography. , 1980, Biochemical and biophysical research communications.